Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

days post last dose, Day 59 Table 4: ISIS 301012 Coadministered with Statins, Laboratory Findings. Number of patients with ALT elevations >/= 3xULN (maximal ALT observed = 211 IU/L). ALT Elevations Single(+) / Placebo 30 mg 100 mg 200 mg 300 mg 400 mg Consecutive(++) (n = 13) (n = 8) (n = 8) (n =16) (n = 8) (n = 8) Primary Endpoint (Day 1 to 59) 0 / 0 0 / 0 0 / 0 1 / 0 0 / 1 1 / 0 Primary Follow-up (Day 60 to 87) 0 / 0 0 / 0 0 / 0 0 / 1 0 / 0 0 / 0 Long term F/U (Day 88 to 199) 0 / 0 0 / 0 0 / 0 0 / 0 NA NA (+) Single = elevation that returned to below 3xULN by the next visit at least 7 days later (++) Consecutive = elevation that was observed in two measures at least 7 days apart Primary endpoint period was 30 days post last dose, Day 59 Primary follow-up period was from primary endpoint to 8 weeks post last dose NA = data not available, cohorts remain in follow-up Presentation Details Date: Monday, March 26, 2007 Session: 820: Clinical Trials of Lipid-Lowering Therapy (4:00 - 5:30 p.m. CT) Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Auditorium B Presentation: 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein Cholesterol and Apolipoprotein B in Hypercholesterolemic Subjects on Statins Not Meeting Target More about Phase 2 Trials for ISIS 301012

Additional data from two studies evaluating ISIS 301012's safety and lipid lowering activity were presented at the ACC. This morning in an ora
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/29/2014)... , July 29, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release second quarter 2014 financial results on Tuesday, ... The Company,s management will hold a conference call ... which is 8:00 p.m., Beijing Time on August 6, ...
(Date:7/29/2014)... --  Health 2.0 announces Bernard Tyson , CEO ... Eric Topol , Patrick Soon-Shiong , and Samsung,s President ... Annual Fall Conference this coming Sept. 21-24 in ... is set to host the very first Wearable Tech Fashion ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The panel ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... 2011 Advanced Life Sciences Holdings, ... cancelled its Annual Meeting of Shareholders, which was previously ...   (Logo:   http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) ... Life Sciences is a biopharmaceutical company engaged in the ...
... Amgen (NASDAQ: AMGN ), today announced results of ... The Fairmont Olympic Hotel in Seattle, Wash. Approximately 86.32 percent ... The director nominees David Baltimore, Frank J. Biondi, Jr., ... C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul ...
Cached Medicine Technology:Amgen Announces Voting Results Of Annual Meeting of Stockholders 2Amgen Announces Voting Results Of Annual Meeting of Stockholders 3Amgen Announces Voting Results Of Annual Meeting of Stockholders 4
(Date:7/29/2014)... significantly reform the federal system for financing physician ... public,s $15 billion annual investment is producing the ... report by the Institute of Medicine. Current ... little accountability, allocates funds independent of workforce needs ... train physicians in the health care settings used ...
(Date:7/29/2014)... The Latin American poultry feed and feed additive ... forecast of revenue. The poultry feed and feed additive market ... and $647.2 million in 2013 to $34,024.0 million and $870.1 ... to 2018, respectively. , To get an idea of the ... the Latin American poultry feed and feed additive market report. ...
(Date:7/29/2014)... 2014 Frank Davis, Activz Founder and ... parents add nutrition to their kids’ meals in the ... market drivers in kids’ foods market” by Kaylynn Chiarello-Ebner. ... announce the interview Frank Davis had with Kaylynn Chiarello-Ebner, ... vegetable and fruit produce powders to kids meals, was ...
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) -- Decorative contact ... you,re not careful, they can cause serious eye damage. ... optometrist or ophthalmologist, according to the U.S. Food and ... exam and a valid prescription for these lenses and ... To spread the word about the potential health ...
(Date:7/29/2014)... State College of Medicine, have jointly received nearly ... data research network., The Patient-Centered Outcomes Research Institute ... and Affordable Care Act, awarded the funds to ... Johns Hopkins University -- and each of their ... together to create a Clinical Data Research Network, ...
Breaking Medicine News(10 mins):Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:New network unites university health care research 2
... Science Center at Houston have developed a chemically modified ... of a genetic bleeding disorder known as Hemophilia A. ... in the May 2 issue of the Journal of ... protein Factor VIII (FVIII), people with Hemophilia A typically ...
... Tax changes drive increased deposits, MINNEAPOLIS, May 19 ... today that Health Savings Accounts (HSAs) deposits,increased 41 percent ... the first time., Wells Fargo Health Benefit Services ... whom took advantage of higher 2007 contribution,limits before the ...
... Commitment to Helping the Uninsured Better ... to Take Care of their Health, ALEXANDRIA, Va., ... prescription savings program created by leading,pharmaceutical companies that is ... million cardholders milestone. The Program, introduced,in January of 2005, ...
... how to treat coronary artery disease, physicians must evaluate ... have found that cognitive decline and neurologic complications, such ... surgery. A new study finds no evidence that bypass ... than patients not undergoing surgery. The study is published ...
... May 19 The American Board of,Medical Specialties ... the United States through its 24 Member Boards,announced ... the public to,enhance physician performance assessment. Called the ... to enhance the ABMS Board,Enterprise,s role as a ...
... May 19 Plastic,surgeons performed more than five ... dog bite wounds and birth defects to removing,tumors ... http://www.newscom.com/cgi-bin/prnh/20080519/DC22812 ), Who are these people? ... their lives?, On average, members of The ...
Cached Medicine News:Health News:Blood-clotting protein modified for people with hard-to-treat hemophilia 2Health News:Wells Fargo Health Savings Accounts Grow to Quarter-Billion Dollars 2Health News:Together Rx Access(R) Program Enrolls More Than 1.5 Million Americans Without Prescription Drug Coverage 2Health News:Together Rx Access(R) Program Enrolls More Than 1.5 Million Americans Without Prescription Drug Coverage 3Health News:Together Rx Access(R) Program Enrolls More Than 1.5 Million Americans Without Prescription Drug Coverage 4Health News:Together Rx Access(R) Program Enrolls More Than 1.5 Million Americans Without Prescription Drug Coverage 5Health News:Long-term cognitive decline in bypass patients not due to surgery 2Health News:ABMS Assembly Votes in Favor of Three-Year Initiative to Enhance Public Trust in the Board Certification Process 2Health News:ABMS Assembly Votes in Favor of Three-Year Initiative to Enhance Public Trust in the Board Certification Process 3Health News:Each Day, Plastic Surgeons Are Reconstructing Lives: Restoring Function, Improving Appearances, and Elevating Self-Esteem 2
Instrument necessary for insertion of Ritleng Bicanaliculus systems and of Self-Threading Monoka systems....
... This unique system uses prolene as thread-guide ... intubation. The hollow Ritleng Probe is inserted ... prolene thread-guide is fed through it. The ... thread to pull the silicone tubing in ...
... system uses prolene as thread-guide reducing time ... hollow Ritleng Probe is inserted into the ... is fed through it. The probe is ... pull the silicone tubing in place. Newly ...
For Canalicular Stenosis in Infants. Medical grade silicone. Note: Can also be used in DCR because of its high flexibility. Probe entirely embedded in silicone tubing (non-traumatic). Box of 3, steri...
Medicine Products: